Alkeon Capital Management LLC Buys 75,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Alkeon Capital Management LLC grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 633,845 shares of the biotechnology company’s stock after purchasing an additional 75,000 shares during the period. Alkeon Capital Management LLC’s holdings in Sarepta Therapeutics were worth $79,161,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Blueshift Asset Management LLC bought a new stake in Sarepta Therapeutics in the third quarter worth $262,000. Finepoint Capital LP raised its stake in shares of Sarepta Therapeutics by 0.5% in the third quarter. Finepoint Capital LP now owns 133,535 shares of the biotechnology company’s stock valued at $16,677,000 after acquiring an additional 700 shares during the period. Quantbot Technologies LP purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $237,000. Qsemble Capital Management LP bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $311,000. Finally, Fisher Asset Management LLC lifted its stake in Sarepta Therapeutics by 1.3% in the third quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company’s stock worth $2,267,000 after purchasing an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SRPT shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Citigroup reduced their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC lowered their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective for the company. Finally, Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Up 5.7 %

Shares of SRPT opened at $137.94 on Friday. The stock has a 50 day moving average price of $122.16 and a 200 day moving average price of $131.43. Sarepta Therapeutics, Inc. has a one year low of $78.67 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a market capitalization of $13.18 billion, a price-to-earnings ratio of 110.35 and a beta of 0.81.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.